PL3668513T3 - Aktywatory kinazy pirogronianowej do leczenia chorób krwi - Google Patents

Aktywatory kinazy pirogronianowej do leczenia chorób krwi

Info

Publication number
PL3668513T3
PL3668513T3 PL18779068T PL18779068T PL3668513T3 PL 3668513 T3 PL3668513 T3 PL 3668513T3 PL 18779068 T PL18779068 T PL 18779068T PL 18779068 T PL18779068 T PL 18779068T PL 3668513 T3 PL3668513 T3 PL 3668513T3
Authority
PL
Poland
Prior art keywords
pyruvate kinase
blood disorders
treating blood
kinase activators
activators
Prior art date
Application number
PL18779068T
Other languages
English (en)
Inventor
Giovanni Cianchetta
Tao Liu
Anil Kumar PADYANA
Zhihua Sui
Zhenwei CAI
Dawei Cui
Jingjing Ji
Original Assignee
Agios Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals, Inc. filed Critical Agios Pharmaceuticals, Inc.
Publication of PL3668513T3 publication Critical patent/PL3668513T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18779068T 2017-08-15 2018-08-15 Aktywatory kinazy pirogronianowej do leczenia chorób krwi PL3668513T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2017097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
PCT/US2018/000128 WO2019035864A1 (en) 2017-08-15 2018-08-15 PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS
EP18779068.8A EP3668513B1 (en) 2017-08-15 2018-08-15 Pyruvate kinase activators for use in treating blood disorders

Publications (1)

Publication Number Publication Date
PL3668513T3 true PL3668513T3 (pl) 2022-03-21

Family

ID=63524352

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18779068T PL3668513T3 (pl) 2017-08-15 2018-08-15 Aktywatory kinazy pirogronianowej do leczenia chorób krwi
PL18766400.8T PL3668512T3 (pl) 2017-08-15 2018-08-15 Modulatory kinazy pirogranianowej i ich zastosowanie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18766400.8T PL3668512T3 (pl) 2017-08-15 2018-08-15 Modulatory kinazy pirogranianowej i ich zastosowanie

Country Status (34)

Country Link
US (8) US11464775B2 (pl)
EP (4) EP3668881B1 (pl)
JP (5) JP7301040B2 (pl)
KR (3) KR102642408B1 (pl)
CN (3) CN111032045B (pl)
AU (4) AU2018316588B2 (pl)
BR (1) BR112020003254A2 (pl)
CA (1) CA3072455A1 (pl)
CL (1) CL2020000375A1 (pl)
CO (2) CO2020002959A2 (pl)
CR (1) CR20200123A (pl)
CY (1) CY1124953T1 (pl)
DK (2) DK3668513T3 (pl)
EC (1) ECSP20018487A (pl)
ES (3) ES2905100T3 (pl)
FI (1) FI3668512T3 (pl)
HR (2) HRP20220039T1 (pl)
HU (2) HUE061910T2 (pl)
IL (3) IL272599B (pl)
LT (2) LT3668513T (pl)
MD (1) MD3668513T2 (pl)
MX (2) MX2020001833A (pl)
MY (1) MY204421A (pl)
PE (1) PE20200724A1 (pl)
PH (1) PH12020500343B1 (pl)
PL (2) PL3668513T3 (pl)
PT (2) PT3668513T (pl)
RS (2) RS62871B1 (pl)
SG (2) SG11202001262QA (pl)
SI (2) SI3668512T1 (pl)
SM (2) SMT202200023T1 (pl)
TW (3) TWI796353B (pl)
UA (1) UA126292C2 (pl)
WO (3) WO2019035864A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
TWI796353B (zh) * 2017-08-15 2023-03-21 美商阿吉歐斯製藥公司 丙酮酸激酶調節劑及其用途
EP3697354A4 (en) 2017-10-20 2021-06-30 The Regents of The University of Michigan EYE DISEASE COMPOSITIONS AND METHODS
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
BR112021015996A2 (pt) * 2019-02-13 2021-11-09 Agios Pharmaceuticals Inc Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes
WO2020262419A1 (ja) * 2019-06-26 2020-12-30 日産化学株式会社 電荷輸送性ワニス
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
EP4185293A4 (en) * 2020-07-21 2025-01-15 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
US11566030B2 (en) 2021-02-08 2023-01-31 Global Blood Therapeutics, Inc. Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023052783A1 (en) * 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
IL312679A (en) * 2021-11-16 2024-07-01 Agios Pharmaceuticals Inc Compounds for the treatment of anemia associated with MDS and other conditions
CN116159061A (zh) * 2023-03-09 2023-05-26 上海市第十人民医院 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用
EP4671102A1 (en) 2023-03-28 2025-12-31 Honda Motor Co., Ltd. METHOD FOR PROVIDING INFORMATION, PROGRAM FOR PROVIDING INFORMATION, STORAGE MEDIA AND INFORMATION PROCESSING APPARATUS
TW202509043A (zh) 2023-05-15 2025-03-01 美商阿吉歐斯製藥公司 ２－（（１ｈ－吡唑－３－基）甲基）－６－（（６－胺基吡啶－２－基）甲基）－４－甲基－４，６－二氫－５ｈ－噻唑基［５＇，４＇：４，５］吡咯并［２，３－ｄ］嗒𠯤－５－酮之結晶形式
KR20260035223A (ko) * 2023-07-05 2026-03-12 아지오스 파마슈티컬스 아이엔씨. 피루브산 키나아제 활성화제의 합성
TW202539675A (zh) 2024-03-27 2025-10-16 美商阿吉歐斯製藥公司 Ｐｋ活化劑在治療鐮狀細胞疾病中之用途
WO2026076363A1 (en) 2024-10-04 2026-04-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
CA2380644A1 (en) 1999-07-30 2001-02-08 Basf Aktiengesellschaft 2-pyrazolin-5-ones
CA2381581A1 (en) 1999-09-04 2001-03-15 Astrazeneca Ab Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
MX2011000843A (es) * 2008-07-23 2011-04-11 Vertex Pharma Inhibidores de pirazolopiridin cinasa triciclicos.
EP2334673A1 (en) * 2008-08-29 2011-06-22 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
WO2010042867A2 (en) 2008-10-09 2010-04-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
CA2758071C (en) * 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
KR101861883B1 (ko) 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
CN103608016A (zh) * 2011-05-03 2014-02-26 安吉奥斯医药品有限公司 丙酮酸激酶激活剂在治疗中的用途
US9388164B2 (en) * 2011-05-03 2016-07-12 Agios Pharmaceuticals, Inc Methods of using pyruvate kinase activators
WO2012151450A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
SMT202400081T1 (it) * 2011-05-03 2024-03-13 Agios Pharmaceuticals Inc Attivatori della piruvato chinasi per uso in terapia
HK1198443A1 (en) * 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
WO2013056153A1 (en) * 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
US9921221B2 (en) 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
EA032007B1 (ru) 2012-11-08 2019-03-29 Аджиос Фармасьютикалз, Инк. Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2
WO2014118135A1 (en) * 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
US11465992B2 (en) 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
AR112475A1 (es) 2017-08-15 2019-10-30 Agios Pharmaceuticals Inc Moduladores de piruvato quinasas y uso de los mismos
US10676485B2 (en) 2017-08-15 2020-06-09 Abbvie Inc. Macrocyclic MCL-1 inhibitors and methods of use
TWI796353B (zh) 2017-08-15 2023-03-21 美商阿吉歐斯製藥公司 丙酮酸激酶調節劑及其用途
BR112021015996A2 (pt) * 2019-02-13 2021-11-09 Agios Pharmaceuticals Inc Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes

Also Published As

Publication number Publication date
JP2020531443A (ja) 2020-11-05
JP2020531432A (ja) 2020-11-05
US20230226055A1 (en) 2023-07-20
BR112020003262A2 (pt) 2020-09-01
KR20200054200A (ko) 2020-05-19
US11590132B2 (en) 2023-02-28
DK3668512T3 (da) 2023-05-22
WO2019035863A1 (en) 2019-02-21
US20210077490A1 (en) 2021-03-18
JP2023052478A (ja) 2023-04-11
CA3072455A1 (en) 2019-02-21
JP2023027276A (ja) 2023-03-01
IL272597B (en) 2022-06-01
MD3668513T2 (ro) 2022-04-30
SI3668512T1 (sl) 2023-06-30
IL292530A (en) 2022-06-01
TWI796353B (zh) 2023-03-21
KR102642408B1 (ko) 2024-02-28
LT3668512T (lt) 2023-06-12
KR20230127364A (ko) 2023-08-31
CN111032045A (zh) 2020-04-17
EP4026838A1 (en) 2022-07-13
WO2019035863A8 (en) 2019-03-28
PL3668512T3 (pl) 2023-06-19
US11364240B2 (en) 2022-06-21
US20210130371A1 (en) 2021-05-06
MX2020001833A (es) 2020-07-22
US20200206225A1 (en) 2020-07-02
US20250144093A1 (en) 2025-05-08
TW202323258A (zh) 2023-06-16
CY1124953T1 (el) 2023-01-05
US20220233541A1 (en) 2022-07-28
EP3668513B1 (en) 2021-11-10
IL272599B (en) 2022-08-01
CR20200123A (es) 2020-06-29
KR102764124B1 (ko) 2025-02-05
TW201919631A (zh) 2019-06-01
CO2020002961A2 (es) 2020-04-13
AU2018316588A1 (en) 2020-02-20
EP3668881B1 (en) 2023-10-04
HUE057178T2 (hu) 2022-04-28
RU2020110573A3 (pl) 2021-12-24
US20220395503A1 (en) 2022-12-15
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
WO2019035864A1 (en) 2019-02-21
US11957680B2 (en) 2024-04-16
SG11202001353PA (en) 2020-03-30
LT3668513T (lt) 2022-03-25
RS62871B1 (sr) 2022-02-28
SMT202200023T1 (it) 2022-03-21
CN111032045B (zh) 2023-08-15
IL272597A (en) 2020-03-31
WO2019035865A1 (en) 2019-02-21
SMT202300146T1 (it) 2023-07-20
CN117186119A (zh) 2023-12-08
IL272599A (en) 2020-03-31
HUE061910T2 (hu) 2023-08-28
IL292530B2 (en) 2023-06-01
SG11202001262QA (en) 2020-03-30
PT3668512T (pt) 2023-05-22
ES2905100T3 (es) 2022-04-07
JP7301040B2 (ja) 2023-06-30
EP3668513A1 (en) 2020-06-24
EP3668881A1 (en) 2020-06-24
JP2024147805A (ja) 2024-10-16
FI3668512T3 (fi) 2023-05-12
AU2018316588B2 (en) 2023-02-02
CN111032046B (zh) 2023-09-26
AU2023202772B2 (en) 2024-05-16
RS64221B1 (sr) 2023-06-30
PE20200724A1 (es) 2020-07-21
RU2020110573A (ru) 2021-09-16
AU2018316587B2 (en) 2023-05-11
KR20200054199A (ko) 2020-05-19
US11464775B2 (en) 2022-10-11
HRP20230452T1 (hr) 2023-07-21
ES2966825T3 (es) 2024-04-24
HRP20220039T1 (hr) 2022-04-15
KR102717594B1 (ko) 2024-10-14
CN117186119B (zh) 2026-04-28
US20200207785A1 (en) 2020-07-02
US11040036B2 (en) 2021-06-22
WO2019035865A8 (en) 2019-03-28
AU2024205818A1 (en) 2024-09-05
AU2018316587A1 (en) 2020-02-20
TWI790271B (zh) 2023-01-21
JP7530453B2 (ja) 2024-08-07
CN111032046A (zh) 2020-04-17
JP7275107B2 (ja) 2023-05-17
US11872225B2 (en) 2024-01-16
PH12020500343B1 (en) 2024-02-21
ES2944545T3 (es) 2023-06-22
DK3668513T3 (da) 2022-01-10
SI3668513T1 (sl) 2022-04-29
UA126292C2 (uk) 2022-09-14
MX2020001832A (es) 2020-07-22
BR112020003254A2 (pt) 2020-10-27
WO2019035864A8 (en) 2019-03-28
TW201920203A (zh) 2019-06-01
MY204421A (en) 2024-08-28
EP3668512A1 (en) 2020-06-24
EP3668512B1 (en) 2023-02-15
ECSP20018487A (es) 2020-05-29
CO2020002959A2 (es) 2020-04-13
CA3071993A1 (en) 2019-02-21
US12133853B2 (en) 2024-11-05
AU2023202772A1 (en) 2023-05-18
CL2020000375A1 (es) 2020-12-11
PH12020500343A1 (en) 2021-02-08

Similar Documents

Publication Publication Date Title
IL292530B2 (en) Pyruvate kinase activators for use in the treatment of blood disorders
IL288231A (en) An inhibitor of jak1/2 or a pharmaceutical salt derived from it and an inhibitor of pi3k or a pharmaceutical salt derived from it, for use in the treatment of myelofibroblasts.
HRP20210518T1 (hr) Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
ZA201707852B (en) Compounds for use in treating neuromuscular disorders
SI3882250T1 (sl) Tetrahidropiranil amino-pirolopirimidinon za uporabo pri zdravljenju z BTK posredovanih motenj
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
ZA201902320B (en) 17alpha,21-diesters of cortexolone for use in the treatment of tumors
IL271020A (en) Tinostemustine for the treatment of sarcoma
HUE054065T2 (hu) Szerek glióma kezelésében történõ alkalmazásra
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
GB201702160D0 (en) Inhibitors for use in therapy
ZA201802399B (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
IL253933A0 (en) History of pyrimidine use in the treatment of cancer
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
GB201615844D0 (en) Agents for use in therapy
HK40030323A (en) Pyruvate kinase activators for use in treating blood disorders